口腔生物医学
口腔生物醫學
구강생물의학
ORAL BIOMEDICINE
2014年
2期
78-81
,共4页
薛昌敖%张建华%刘炜%吴煜农
薛昌敖%張建華%劉煒%吳煜農
설창오%장건화%류위%오욱농
神经γ突触核蛋白%基质金属蛋白酶-9%口腔颌面部鳞癌%免疫组化
神經γ突觸覈蛋白%基質金屬蛋白酶-9%口腔頜麵部鱗癌%免疫組化
신경γ돌촉핵단백%기질금속단백매-9%구강합면부린암%면역조화
Synuclein gamma%Matrix metalloproteinase-9%Oral and maxillofacial carcinoma%Immunohistochemistry
目的：探讨神经突触核蛋白-γ（synuclein gamma，SNCG）及基质金属蛋白酶-9（matrix metalloproteinase-9，MMP-9）在鳞状细胞癌及癌旁组织的表达，分析其与肿瘤的临床及病理特征相关性。方法：采用免疫组化 EnVision 二步法检测150例鳞状细胞癌及癌旁组织中 SNCG 及 MMP-9的表达。结果：口腔颌面部鳞癌组织中的 SNCG 及 MMP-9的阳性率分别为78．0％（117/150）及68．68％（103/150），而癌旁组织中 SNCG及 MMP-9的阳性率分别为8．0％（11/150）及14．0％（21/150），均有显著性差异（P＜0．001）。低分化、中分化肿瘤的 SNCG及 MMP-9的表达阳性率显著高于高分化肿瘤中的阳性率（P＜0．001），然而低分化与中分化肿瘤之间 SNCG及 MMP-9的表达阳性率无显著性差异（P＞0．05）。肿瘤分期分析结果显示，Ⅲ～Ⅳ期SNCG及 MMP-9的表达阳性率显著高于Ⅰ～Ⅱ期，有显著性差异（SNCG：χ2＝4．20，P＝0．041；MMP-9：χ2＝26．66，P＝0．000）。转移的肿瘤组织中的SNCG及MMP-9的表达阳性率分别为90．77％和93．85％，高于其在无转移的肿瘤组织表达阳性率，有显著性差异（SNCG：χ2＝10．09，P＝0．001；MMP-9：χ2＝33．80，P＝0．000）结论：SNCG、MMP-9在与口腔颌面部鳞癌中呈现高表达，与肿瘤的病理与临床分级、分期呈正相关，提示检测口腔颌面部鳞癌组织中 SNCG及 MMP-9的表达可以为肿瘤的病情进展和预后判断提供依据。
目的：探討神經突觸覈蛋白-γ（synuclein gamma，SNCG）及基質金屬蛋白酶-9（matrix metalloproteinase-9，MMP-9）在鱗狀細胞癌及癌徬組織的錶達，分析其與腫瘤的臨床及病理特徵相關性。方法：採用免疫組化 EnVision 二步法檢測150例鱗狀細胞癌及癌徬組織中 SNCG 及 MMP-9的錶達。結果：口腔頜麵部鱗癌組織中的 SNCG 及 MMP-9的暘性率分彆為78．0％（117/150）及68．68％（103/150），而癌徬組織中 SNCG及 MMP-9的暘性率分彆為8．0％（11/150）及14．0％（21/150），均有顯著性差異（P＜0．001）。低分化、中分化腫瘤的 SNCG及 MMP-9的錶達暘性率顯著高于高分化腫瘤中的暘性率（P＜0．001），然而低分化與中分化腫瘤之間 SNCG及 MMP-9的錶達暘性率無顯著性差異（P＞0．05）。腫瘤分期分析結果顯示，Ⅲ～Ⅳ期SNCG及 MMP-9的錶達暘性率顯著高于Ⅰ～Ⅱ期，有顯著性差異（SNCG：χ2＝4．20，P＝0．041；MMP-9：χ2＝26．66，P＝0．000）。轉移的腫瘤組織中的SNCG及MMP-9的錶達暘性率分彆為90．77％和93．85％，高于其在無轉移的腫瘤組織錶達暘性率，有顯著性差異（SNCG：χ2＝10．09，P＝0．001；MMP-9：χ2＝33．80，P＝0．000）結論：SNCG、MMP-9在與口腔頜麵部鱗癌中呈現高錶達，與腫瘤的病理與臨床分級、分期呈正相關，提示檢測口腔頜麵部鱗癌組織中 SNCG及 MMP-9的錶達可以為腫瘤的病情進展和預後判斷提供依據。
목적：탐토신경돌촉핵단백-γ（synuclein gamma，SNCG）급기질금속단백매-9（matrix metalloproteinase-9，MMP-9）재린상세포암급암방조직적표체，분석기여종류적림상급병리특정상관성。방법：채용면역조화 EnVision 이보법검측150례린상세포암급암방조직중 SNCG 급 MMP-9적표체。결과：구강합면부린암조직중적 SNCG 급 MMP-9적양성솔분별위78．0％（117/150）급68．68％（103/150），이암방조직중 SNCG급 MMP-9적양성솔분별위8．0％（11/150）급14．0％（21/150），균유현저성차이（P＜0．001）。저분화、중분화종류적 SNCG급 MMP-9적표체양성솔현저고우고분화종류중적양성솔（P＜0．001），연이저분화여중분화종류지간 SNCG급 MMP-9적표체양성솔무현저성차이（P＞0．05）。종류분기분석결과현시，Ⅲ～Ⅳ기SNCG급 MMP-9적표체양성솔현저고우Ⅰ～Ⅱ기，유현저성차이（SNCG：χ2＝4．20，P＝0．041；MMP-9：χ2＝26．66，P＝0．000）。전이적종류조직중적SNCG급MMP-9적표체양성솔분별위90．77％화93．85％，고우기재무전이적종류조직표체양성솔，유현저성차이（SNCG：χ2＝10．09，P＝0．001；MMP-9：χ2＝33．80，P＝0．000）결론：SNCG、MMP-9재여구강합면부린암중정현고표체，여종류적병리여림상분급、분기정정상관，제시검측구강합면부린암조직중 SNCG급 MMP-9적표체가이위종류적병정진전화예후판단제공의거。
Objective:To analyze the correlation between synuclein gamma (SNCG)and matrix metalloproteinase-9 (MMP-9)and the clinicopathological features of tumor,we investigated the expression of SNCG and MMP-9 in oral and maxillofacial carcinoma and its adjacent tissues.Methods:Immunohistochemistry method was used to detect the expression of SNCG and MMP-9 in oral and maxillofa-cial carcinoma and its adjacent tissues.Results:The incidence rate of SNCG and MMP-9 in oral and maxillofacial carcinoma was 78.0% (1 17/150)and 68.68%(103/150),respectively.While that of SNCG and MMP-9 in its adjacent tissues was 8.0%(1 1/150) and 14.0%(21/150),respectively.There were significantly differences in SNCG and MMP-9 between them(P <0.001).The inci-dence rates of SNCG and MMP-9 were higher in poorly or medium differentiated (P<0.001 ).However,the expression of SNCG and MMP-9 between poorly differentiated and well differentiated carcinoma had no significant difference.According to stages,the incidence rates of SNCG and MMP-9 in Ⅲ-Ⅳ period were significantly higher than those inⅠ-Ⅱ period,and there were significant difference (SNCG:χ2 =4.20,P=0.041;MMP-9:χ2 =26.66,P=0.000).The expression of SNCG and MMP-9 in metastatic tumor were higher (SNCG:90.77%;MMP-9:93.85% )than that in non-metastatic tumor (SNCG:68.24%;MMP-9:49.41%),and there were sig-nificant difference(SNCG:χ2 =10.09,P=0.0014;MMP-9:χ2 =33.80,P=0.000).Conclusions:The excessive expression of SNCG and MMP-9 in oral and maxillofacial carcinoma,which was positively associated with the pathologic process,differentiation degree of carcinoma,and TNM stages of tumor.The expression of SNCG and MMP-9 are expected to be the marker in the tumor of oral and maxil-lofacial carcinoma for the judgment of advancement and prognosis.
